Linked Life Data

17714018

Source:http://linkedlifedata.com/resource/pubmed/id/17714018

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
9
pubmed:dateCreated
2007-8-23
pubmed:abstractText
Although bladder cancer is a chemosensitive tumor, metastatic disease is related with poor prognosis and short-term survival. For two decades, the treatment of choice for metastatic bladder cancer has been cisplatin-based chemotherapy. Nowadays, non-platinum regimes have been tested such as taxanes and gemcitabine, which is considered as an attractive alternative. In parallel, double and triplet combination chemotherapy have been assessed in clinical trials. Furthermore, individualized treatments through the identification of molecular prognostic factors and application of targeted therapy have gained considerable interest.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
1744-7658
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
16
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1311-4
pubmed:meshHeading
pubmed:year
2007
pubmed:articleTitle
Where are we with the treatment of metastatic bladder cancer?
pubmed:affiliation
Agios Andreas Regional Hospital, Department of Urology, Patras, Greece. agpapatsoris@yahoo.gr
pubmed:publicationType
Journal Article